Becaplermin
- Generic Name
- Becaplermin
- Brand Names
- Regranex
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 165101-51-9
- Unique Ingredient Identifier
- 1B56C968OA
- Background
Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together by disulfide bonds.
- Indication
For topical treatment of skin ulcers (from diabetes)
- Associated Conditions
- Skin Ulcer
- Associated Therapies
- -
Becaplermin Gel for MARTORELL's Hypertensive Leg Ulcers
Phase 3
Completed
- Conditions
- MARTORELL'S ULCERHypertensive Leg UlcerNecrotic Angiodermatitis
- Interventions
- Drug: Duoderm Hydrogel™Drug: becaplermin gel
- First Posted Date
- 2009-09-02
- Last Posted Date
- 2011-10-04
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 64
- Registration Number
- NCT00970697
- Locations
- 🇫🇷
Hospital Charles Foix, Ivry sur seine, Ile de France, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath